Severe Sepsis and Septic Shock
4
0
0
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 4 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Statistical Analysis Plan for an Individual Patient Data Meta-analysis of Three, International Trials Comparing Protocolised With Usual Resuscitation in Patients Presenting to the Emergency Department With Severe Sepsis and Septic Shock
Membrane Shedding During Severe Sepsis and Septic Shock: Pathophysiological and Clinical Relevance
Comparison of Sensitivity Between Presepsine and Lactate for the Diagnosis of Severe Sepsis.
Extracorporeal Immune Support System (EISS) for the Treatment of Septic Patients